FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Washington, I	D.C.	20549	
---------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0283								
Estimated average burden								
hours ner resnonse.	0.5							

					or 8	Secti	on 30(h) d	or the	investmer	nt Col	mpany Act	ot 1940							
1. Name and Address of Reporting Person* Multani Pratik S					2. Issuer Name and Ticker or Trading Symbol Oric Pharmaceuticals, Inc. [ORIC]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
- IVIGITALI	I I I I I I I I I	-													Officer	r (give title		Other (s	
(1 1)	/5		/N 41 -1 -11 - \											- I	below)			below)	pecity
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)								Chief Medical Officer					
C/O ORIC PHARMACEUTICALS, INC.			02/01/2021																
240 E. GRAND AVE., 2ND FLOOR																			
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
SOUTH	SAN) Line,		led by One	Renc	orting Person	,
FRANCI	()	A	94080											1	_	,		n One Repor	
															Persor		e triai	i One ixepoi	ung
(City)	(S	tate)	(Zip)																
		Tab	le I - Non-	-Deriva	tive	Se	curities	s Ac	quired,	Dis	posed o	f, or Be	enef	icially	y Owned				
Date				Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr						ies Fo cially (D Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or Pr		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
		-	Table II - D								osed of, convertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\)	′ Co	Transactio Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nui of	mber ares					
Stock Option (right to buy)	\$29.83	02/01/2021		1	A		90,000		(1)		01/31/2031	Common Stock	90	,000,	\$0.00	90,000	0	D	

Explanation of Responses:

1. 25% of the shares subject to the option shall vest on February 1, 2022, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

Remarks:

/s/ Dominic Piscitelli, attorney-02/02/2021 in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.